Skip to content

    Diabetes Health Center

    Font Size
    A
    A
    A

    Sales of Inhaled Insulin Exubera Halted

    Drug Company Cites Financial Reasons for Removing Exubera From Market
    By
    WebMD Health News

    Oct. 18, 2007 -- The drug company Pfizer announced that it will stop selling its inhaled insulin product Exubera for financial reasons.

    In January 2006, Exubera became the first inhaled insulin to get FDA approval. Exubera delivers short-acting insulin via an inhaler, providing an alternative to insulin injections.

    "Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted," Jeff Kindler, Pfizer's chairman and CEO, says in a Pfizer news release.

    "We will work with physicians to transition Exubera patients to other treatment options in the next three months," says Kindler.

    "We remain committed to investing significant resources in the development of new and innovative medicines to manage diabetes, including monitoring inhalation technologies and other innovative delivery systems for insulin and other medicines," says Kindler.

    Today on WebMD

    Diabetic tools
    Symptoms, diagnosis, treatment, and more.
    woman flexing muscles
    10 strength training exercises.
     
    Blood sugar test
    12 practical tips.
    Tom Hanks
    Stars living with type 1 or type 2.
     
    kenneth fujioka, md
    Video
    Can Vinegar Treat Diabetes
    Article
     
    Middle aged person
    Tool
    jennie brand miller
    Video
     

    Prediabetes How to Prevent Type 2 Diabetes
    Article
    type 2 diabetes
    Slideshow
     
    food fitness planner
    Tool
    feet
    Slideshow